Retraction notice to "Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial" [International Journal of Antimicrobial Agents 56 (2020), 105949].
作者信息
Gautret Philippe, Lagier Jean-Christophe, Parola Philippe, Hoang Van Thuan, Meddeb Line, Mailhe Morgane, Doudier Barbara, Courjon Johan, Giordanengo Valérie, Vieira Vera Esteves, Dupont Hervé Tissot, Honoré Stéphane, Colson Philippe, Chabrière Eric, La Scola Bernard, Rolain Jean-Marc, Brouqui Philippe, Raoult Didier
机构信息
IHU-Méditerranée Infection, Marseille, France; Aix Marseille Univ, IRD, AP-HM, SSA, VITROME, Marseille, France.
IHU-Méditerranée Infection, Marseille, France; Aix Marseille Univ, IRD, APHM, MEPHI, Marseille, France.
出版信息
Int J Antimicrob Agents. 2025 Jan;65(1):107416. doi: 10.1016/j.ijantimicag.2024.107416. Epub 2024 Dec 26.
Abstract
摘要
相似文献
1
Retraction notice to "Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial" [International Journal of Antimicrobial Agents 56 (2020), 105949].
Int J Antimicrob Agents. 2025 Jan;65(1):107416. doi: 10.1016/j.ijantimicag.2024.107416. Epub 2024 Dec 26.
2
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Int J Antimicrob Agents. 2020 Jul;56(1):105949. doi: 10.1016/j.ijantimicag.2020.105949. Epub 2020 Mar 20.
3
Doxycycline vs Hydroxychloroquine + Azithromycin in the Management of COVID-19 Patients: An Open-Label Randomized Clinical Trial in Sub-Saharan Africa (DOXYCOV).
Cureus. 2023 Sep 20;15(9):e45619. doi: 10.7759/cureus.45619. eCollection 2023 Sep.
4
Focus on clinical outcomes of "Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial".
Int J Antimicrob Agents. 2021 Jan;57(1):106175. doi: 10.1016/j.ijantimicag.2020.106175.
5
Letter to the editor about "Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial".
Int J Antimicrob Agents. 2021 Jan;57(1):106171. doi: 10.1016/j.ijantimicag.2020.106171.
6
Referring to the study: Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial.
Int J Antimicrob Agents. 2021 Jan;57(1):106176. doi: 10.1016/j.ijantimicag.2020.106176.
7
Pakistan Randomized and Observational Trial to Evaluate Coronavirus Treatment (PROTECT) of Hydroxychloroquine, Oseltamivir and Azithromycin to treat newly diagnosed patients with COVID-19 infection who have no comorbidities like diabetes mellitus: A structured summary of a study protocol for a randomized controlled trial.
Trials. 2020 Aug 8;21(1):702. doi: 10.1186/s13063-020-04616-4.
8
Direct antivirals working against the novel coronavirus: azithromycin (DAWn-AZITHRO), a randomized, multicenter, open-label, adaptive, proof-of-concept clinical trial of new antivirals working against SARS-CoV-2-azithromycin trial.
Trials. 2021 Feb 9;22(1):126. doi: 10.1186/s13063-021-05033-x.
9
Review of: "Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial Gautret et al 2010, DOI:10.1016/j.ijantimicag.2020.105949.
Int J Antimicrob Agents. 2020 Jul;56(1):106063. doi: 10.1016/j.ijantimicag.2020.106063. Epub 2020 Jul 13.
10
Efficacy of Ivermectin, Chloroquine/Hydroxychloroquine, and Azithromycin in Managing COVID-19: A Systematic Review of Phase III Clinical Trials.
Biomedicines. 2024 Sep 27;12(10):2206. doi: 10.3390/biomedicines12102206.
引用本文的文献
1
COVID-19 and a Tale of Three Drugs: To Repurpose, or Not to Repurpose-That Was the Question.
Viruses. 2025 Jun 23;17(7):881. doi: 10.3390/v17070881.
2
Coronavirus in Continuous Flux: From SARS-CoV to SARS-CoV-2.
Adv Sci (Weinh). 2020 Aug 16;7(20):2001474. doi: 10.1002/advs.202001474. eCollection 2020 Oct.
Zotero 插件